Cannabidiol for treating seizures caused by tuberous sclerosis complex
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about cannabidiol
Marketing authorisation indication
2.1 Cannabidiol (Epidyolex, GW Research Ltd) is indicated 'for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for cannabidiol.
Price
2.3 The list price is £850.29 per 100‑ml (100 mg/ml) bottle. The company has a commercial arrangement, which would have applied if the technology had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions